News Column

New Lymphoma Study Findings Have Been Reported by Researchers at Medical College of Wisconsin

February 26, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Lymphoproliferative Disorders are presented in a new report. According to news originating from Milwaukee, Wisconsin, by NewsRx correspondents, research stated, "Trends in utilization and outcomes after autologous or allogeneic hematopoietic cell transplantation (HCT) for Burkitt lymphoma were analyzed in 241 recipients reported to the Center for International Blood and Marrow Transplant Research between 1985 and 2007. The autologous HCT cohort had a higher proportion of chemotherapy-sensitive disease, peripheral blood grafts, and HCT in first complete remission (CR1)."

Our news journalists obtained a quote from the research from the Medical College of Wisconsin, "The use of autologous HCT has declined over time, with only 19% done after 2001. Overall survival at 5 years for the autologous cohort was 83% for those in CR1 and 31% for those not in CR1. Corresponding progression-free survival (PFS) was 78% and 27%, respectively. After allogeneic HCT, overall survival at 5 years was 53% and 20% for the CR1 and non-CR1 cohorts, whereas PFS was 50% and 19%, respectively. The most common cause of death was progressive lymphoma. Allogeneic HCT performed in a higher-risk subset (per National Comprehensive Cancer Network guidelines) resulted in a 5-year PFS of 27%."

According to the news editors, the research concluded: "Autologous HCT resulted in a 5-year PFS of 44% in those undergoing transplantation in the second CR."

For more information on this research see: Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation, 2013;19(2):173-9. (Elsevier -; Biology of Blood and Marrow Transplantation -

The news correspondents report that additional information may be obtained from L.V. Maramattom, Hematology, Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States. Additional authors for this research include P.N. Hari, L.J. Burns, J. Carreras, W. Arcese, M.S. Cairo, L.J. Costa, T.S. Fenske, M. Lill, C.O. Freytes, R.P. Gale, T.G. Gross, G.A. Hale, M. Hamadani, L.A. Holmberg, J.W. Hsu, D.J. Inwards, H.M. Lazarus and D Marks (see also Lymphoproliferative Disorders).

Keywords for this news article include: Drugs, Lymphoma, Oncology, Milwaukee, Wisconsin, Hematology, Chemotherapy, United States, Lymphatic Diseases, North and Central America, Immunoproliferative Disorders, Lymphoproliferative Disorders.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools